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Aims: To assess the prevalence of stage 3–5 chronic kidney disease (CKD) at baseline and to identify associated
risk factors. To determine the effect of CKD and CKD stage according to estimated glomerular ﬁltration rate
(eGFR) and albuminuria categories on all-cause and cardiovascular mortality after a 5-year follow-up.
Methods: Prospective cohort study of 3443 outpatients with type 2 diabetes mellitus.
Results: The prevalence of CKD was 28.32% (95% CI, 26.84–29.86); and variables most strongly associated
were: age N74 years (OR, 19.88; 95% CI, 12.89–30.68) and albuminuria (OR, 2.27; 95% CI, 1.72–3.00).
During follow-up, 221 CKD patients (22.90%) died compared with 203 non-CKD patients (8.31%) (p b 0.01).
The adjusted HR of CKD for cardiovascular and all-cause mortality was 1.82 (95% CI, 1.36–2.44) and 2.11 (95%
CI, 1.61–2.76) for those with LDL cholesterol =135 mg/dl, respectively. The adjusted HR of very-high-risk
CKD for all-cause mortality was 4.44 (95% CI, 2.31–8.53) in aged b75 years and 1.80 (95% CI, 1.19–2.72) in
aged ≥75 years.
Conclusions: CKD at baseline is an independent risk factor for all-cause and cardiovascularmortality in the overall
cohort, men and women, or in primary and secondary prevention of coronary heart disease. Albuminuria is an
independent risk factor for all-cause and cardiovascular mortality only in primary prevention.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Chronic kidney disease (CKD) is deﬁned as the presence of kidney
damage (i.e., albuminuria) or decreased kidney function for at leasthave no competing interests
istry of Science and Innovation
2/01806). The funders had no
ision to publish, or preparation
.Á. Salinero-Fort).
Inc. This is an open access article u3 months, irrespective of clinical diagnosis (National Kidney Foundation,
2002). CKD is a worldwide public health problem and a well-known
epidemiologic risk factor that can be used to predict cardiovascular
morbidity (Sarnak et al., 2003) and long-term mortality (Coladonato,
Klassen, & Owen, 2002). The prevalence of CKD is growing worldwide
owing to the increased frequency of associated chronic diseases such as
type 2 diabetesmellitus (T2DM) and hypertension (Haroun et al., 2003).
The Kidney Disease Improving Global Outcomes (KDIGO) organi-
zation has developed a clinical practice guideline for the evaluation
and management of CKD (KDIGO, 2013) that includes a prognostic
classiﬁcation of CKD based on glomerular ﬁltration rate (GFR) and
albuminuria. The guideline also takes into account epidemiologicalnder the CCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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disease, acute kidney injury, progression of CKD, all-cause mortality,
and cardiovascular mortality) from 45 cohorts. The classiﬁcation
includes 4 risk categories for adverse outcome: low, moderate, high,
and very high.
To our knowledge, very few cohort studies have analyzed the
prevalence of CKD measured at baseline in southern European
patients diagnosed with T2DM (Targher et al., 2012). Similarly, few
authors have investigated mortality risk in a prognostic classiﬁcation
of CKD by albuminuria categories and estimated glomerular ﬁltration
rate (eGFR) in Mediterranean countries (Toyama et al., 2013).
We studied a cohort of Spanish T2DM patients attending primary
care centers in order to assess the prevalence of stage 3–5 CKD at
baseline and to identify associated risk factors. We also determined
the effect of CKD and risk categories of an adverse outcome on all-cause
and cardiovascular mortality after a 5-year follow-up period.
2. Subjects
The MADrid DIABETES Study (MADIABETES Study) is a prospective
cohort study of 3443 T2DMoutpatients that has beendescribed in detail
elsewhere (Salinero-Fort et al., 2013). Brieﬂy, the study participants
were selected using simple random sampling by participating general
practitioners (n = 131) from 56 primary health care centers in the
metropolitan area of Madrid (Spain) based on the list of patients with a
diagnosis of T2DM in their computerized clinical records.
3. Material and methods
General practitioners collected data at the baseline visit (2007) and
annually during the follow-up period (2008–2012). The data were
recorded on electronic case report forms hosted on the website www.
madiabetes.com. The inclusion criteria were age ≥30 years, a previous
diagnosis of T2DM, and written informed consent to participate in
the study. The exclusion criteriawere type 1 DMand being homebound.
For this analysis, 36 patients were excluded owing to missing serum
creatinine values; the remaining 3407 patients constituted the
MADIABETES CKD Cohort.
3.1. Outcomes: deﬁnition and measurement
The CKD stages were classiﬁed according to the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI)
(National Kidney Foundation, 2002). For the purposes of this study,
CKD was deﬁned as K/DOQI stage 3–5 CKD.
Patients were classiﬁed according to the risk of adverse outcomes.
Four categories of risk were established (low, moderate, high and very
high) based on values of albuminuria and eGFR, as indicated elsewhere
[see Figure 2 from Levey et al. (2011) that provides the deﬁnitions of the
categories].
eGFR was calculated using the CKD-EPI equation, which has
proven to be a more accurate predictor of the risk of death in patients
with T2DM (Targher et al., 2012), and is recommended by the 2012
KDIGO Clinical Practice Guidelines (Inker et al., 2014). The equation is
especially suitable for elderly patients (Kilbride et al., 2013).
3.1.1. Clinical examination and biochemistry
A clinical history was taken, and patients underwent a physical
examination and biochemical tests. The variables collected at baseline
were age, gender, duration of DM (years), fasting plasma glucose,
glycated hemoglobin (HbA1c), systolic blood pressure (SBP) and
diastolic blood pressure (DBP), total cholesterol, triglycerides (TG),
high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), albuminuria, smoking status (current smoker,
former smoker, non-smoker), use of hypoglycemic and cardiovascular
medications (antihypertensive agents, statins, aspirin), bodymass index(BMI), and history of cardiovascular events (myocardial infarction,
peripheral artery disease or stroke) and hypertension.
BMI was calculated as weight/height2 (kg/m2). Blood pressurewas
measured using a calibrated sphygmomanometer. Hypertension was
deﬁned as SBP 140 mmHg or more, and/or diastolic blood pressure
90 mmHg or more; or prior diagnosis of arterial hypertension and/or
use of antihypertensive medication. After a 5-min rest period, the ﬁrst
reading was taken, followed by a second reading 5 min later.
Dyslipidemia was deﬁned as either of the following lipid
alterations: 1) total cholesterol concentration ≥190 mg/dl in patients
with a history of cardiovascular disease (CVD) and ≥240 mg/dl or
more in patients without a history of CVD, and/or TG N 200 mg/dl; or 2)
LDL-C N130 mg/dl and/or HDL-C b35/45 mg/dl (male/female, respectively),
or prior diagnosis of dyslipemia and/or use of lipid-lowering drugs.
Serum creatinine was measured using an enzymatic creatinine
assay that was not traceable to isotope dilution mass spectrometry
(ID-MS), and the value was included in the equation used to estimate
GFR as follows: serum creatinine (Jaffe's method) = 1.0302 × serum
creatinine (enzymatic method) + 0.2648 [r = 0.999, p b 0.001].
Persistent microalbuminuria was deﬁned as a urinary albumin
excretion rate ≥30 mg/g and b300 mg/g in at least 2 of 3 consecutive
samples; macroalbuminuria was deﬁned as a urinary albumin
excretion rate ≥300 mg/g. HbA1c was measured using high-perfor-
mance liquid chromatography (Diabetes Control and Complications
Trial-aligned) (Selvin, Coresh, Zhu, Folsom, & Steffes, 2010).
Cardiovascular riskwas calculated following theREGICOR formula (a
calibration of the Framingham algorithm adapted for Spain) (Marrugat
et al., 2003) for each patient free of CVD at the baseline examination in
2007 (n = 1869). Patientswith a cardiovascular risk of 10%over 10 years
were considered moderate- or high-risk (Bosomworth, 2011).
Retinopathy was diagnosed as the presence of any of the following
lesions: microaneurysm, intraretinal hemorrhage, venous beading,
neovascularization, vitreous/preretinal hemorrhage, cotton wool
spots, retinal thickening, and hard exudates. The stage of retinopathy
was based on the severity scale proposed by Wilkinson et al. (2003).
In the absence of photographic records, it was difﬁcult to determine
the number of microaneurysms per quadrant; therefore, we simpliﬁed
categorization of nonproliferative diabetic retinopathy to 2 categories,
namely, mild and moderate/severe.
After the 5-year follow-up, the vital status of the diabetic cohort
was ascertained on 31December 2012 from themortality records of the
Spanish National Institute of Statistics (Instituto Nacional de Estadística,
http://www.ine.es). The underlying cause of death stated on the
death certiﬁcateswas codedaccording to the International Classiﬁcation
of Diseases, Tenth Revision (World Health Organization, 2004) and
cardiovascular mortality was deﬁned as death due to myocardial
infarction, heart failure, stroke, or sudden cardiac death.
4. Statistical analysis
Descriptive datawere expressed asmean and standard deviation and
median and IQR. Continuous variables were compared between the 2
groups using the t test for normal distributions and the Mann–Whitney
test for non-normal distributions; categorical variables were compared
using the chi-square test. The multivariable analysis of variables
associated with CKD at baseline was by logistic regression. The variables
for the adjustment were selected on the basis of signiﬁcant bivariate
relationshipsor clinical relevance. Statistical signiﬁcancewas set at≤0.05,
with a 95% conﬁdence interval (95% CI).
Mortality was expressed in terms of cumulative incidence and
incidence density (cases per 1000 person-years of follow-up). Life
tables (actuarial method) were used to calculate death and survival
rates. In the bivariate analysis, survival curves were constructed, and
the statistical signiﬁcance of survival differences for each variable
(CKD vs. non-CKD and 4 categories of risk of developing adverse
outcomes according to eGFR and albuminuria level) was determined
Table 1
Baseline characteristics of the MADIABETES CKD Cohort (N = 3407), stratiﬁed by CKD at baseline.
N = 3407 95% CI CKD (n = 965) Non-CKD (n = 2442) p value
Sociodemographic variables
Female gender (%) 49.7 48.0–51.4 61.3 45.1 b0.001
Age (yr), mean (SD) 69 (10.8) 68.7–69.4 75.7 (8.2) 66.4 (10.6) b0.001
Duration of DM (yr), mean (SD) 9.1 (7.7) 8.8–9.3 10.9 (8.7) 8.3 (7.2) b0.001
Duration of DM (yr), median (IQR) 7 (8) 7–7 8 (10) 6 (7) b0.001
Current smoker, (%) 15.8 14.6–17.1 9 18.6 b0.001
Former smoker, (%) 25.4 23.9–26.9 18.9 27.9 b0.001
Non-smoker, (%) 58.8 57.1–60.4 72.1 53.5 b0.001
Medication Proﬁle (%)
Oral antidiabetic alone 60.4 58.8–62.1 52.3 63.6 b0.001
Insulin alone 6.9 6.1–7.8 11.4 5.1 b0.001
Oral antidiabetic + Insulin 13.6 12.5–14.8 17.9 11.9 b0.001
Antihypertensive agents 84.9 83.7–86.1 95.4 80.8 b0.001
Aspirin 51 49.3–52.7 58.2 48.2 b0.001
Statins 71.7 70.1–73.2 72.7 71.2 0.393
History of (%)
Hypertension 74.1 72.6–75.5 86.6 69.1 b0.001
Myocardial Infarction 12.7 11.6–13.8 17.6 10.7 b0.001
Stroke 8.3 7.5–9.3 12.6 6.6 b0.001
Peripheral artery disease 7.3 6.5–8.2 10.6 5.9 b0.001
Congestive heart failure 6.9 6.1–7.8 11.1 5.2 b0.001
Number of Cardiovascular events
0 (%) 74.6 72.7–75.7 69.8 76.5 b0.001
1 (%) 17.8 16.5–19.1 23.7 15.4 b0.001
2 (%) 6.8 6.0–7.6 10.8 5.2 b0.001
N2 (%) 1.32 0.9–1.7 2.2 0.9 b0.001
Neuropathy 7.2 6.4–8.1 9 6.5 0.011
Retinopathy 8.8 7.9–9.8 12.6 7.3 b0.001
Neuropathy + Retinopathy 1.9 1.5–2.4 3.2 1.4 b0.001
Risk of developing coronary events
Number of Patients free CVD at baseline (%) 2543 (74.6) 674 (69.8) 1869 (76.5)
Adjusted REGICOR function 10-year risk, mean (SD) 5.8 (2.9) 5.7–5.9 5.8 (2.9) 5.9 (2.9) 0.465
Percentage of patients with risk b5% 53.3 51.5–55.1 55 52.6 0.445
Percentage of patients with risk 5%–10% 37.6 35.9–39.3 36.6 37.7
Percentage of patients with risk N10% 9.1 8.1–10.1 8.3 9.6
Anthropometric variables
BMI (kg/m2), mean (SD) 30.1 (4.9) 29.9–30.3 30.1 (5) 30.1 (4.9) 0.949
SBP (mmHg), mean (SD) 133.8 (13.5) 133.3–134.2 134.7 (13) 133.4 (13.6) 0.013
DBP (mmHg), mean (SD) 76.8 (7.9) 76.5–77.1 75.2 (7.3) 77.5 (8.1) b0.001
Laboratory variables
eGFR (mL/min/1.73 m2), mean (SD) 70.5 (17.8) 69.9–71.1 48.9 (9.4) 79.1 (12.2) b0.001
eGFR (mL/min/1.73 m2), median (IQR) 70.7 (25.5) 69.8–71.5 51.4 (12.2) 78.1 (18.9) b0.001
FPG (mg/dl), mean (SD) 143.4 (41.4) 141.9–144.9 139.8 (41.1) 144.8 (41.5) 0.002
FPG (mg/dl), median (IQR) 135 (43) 134–137 133 (44) 136 (42) 0.001
Patients with HbA1c level b7, (%) 53.8 52.1–55.5 55.2 53.2 0.313
HbA1c (%), mean (SD) 7.1 (1.2) 7.1–7.2 7.05 (1.1) 7.1 (1.2) 0.188
HbA1c (%), median (IQR) 6.9 (1.4) 6.8–6.9 6.9 (1.3) 6.9 (1.4) 0.265
Dyslipidemia, (%) 56.3 54.6–57.9 52.7 57.7 0.009
Total cholesterol (mg/dl), mean (SD) 192 (36.1) 190.8–193.2 188.8 (37.1) 193.2 (35.6) 0.001
LDL-C (mg/dl), mean (SD) 115.1 (29.9) 114.1–116.2 112.3 (30.3) 116.2 (26.9) 0.001
HDL-C (mg/dl), mean (SD) 48.9 (12.9) 48.5–49.4 48.7 (14) 49 (12.5) 0.562
Triglycerides (mg/dl), mean (SD) 145.3 (91.4) 142.2–148.5 144.3 (78) 145.8 (96) 0.687
Triglycerides (mg/dl), median (IQR) 123 (78) 121–125 127 (75) 122 (80) 0.037
Albuminuria2 (%) 10.9 9.9–11.9
Microalbuminuria 10.1 9.1–11.1 15.6 7.8 b0.001
Macroalbuminuria 0.8 0.6–1.2 1.8 0.5 b0.001
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hazard analysis including age, gender, and history of cardiovascular
events (myocardial infarction, stroke, peripheral arterydisease)wasused
to estimate the adjusted hazard ratio (aHR) and corresponding 95% CI for
incident all-causemortality associatedwith bothCKD(model 1) andCKD
prognosis stage (model 2), respectively.
If the CIs of the mortality rates overlapped, we considered that the
differences were not statistically signiﬁcant.
In order to analyze the effect of CKD on cardiovascular and all-cause
mortality, a multivariable Cox regression analysis with each mortality
outcome was conducted for the overall sample, and stratiﬁed by gender
and prior CVD. The adjustment variables, when it was necessary, were:
gender, age, history of CVD or heart failure, body mass index, SBP, total
cholesterol, LDL cholesterol, tryglycerides, albuminuria, insulin, statins,antiplatelet theraphy, and renin–angiotensin system inhibitors. The
procedure was repeated to analyze the effect of CKD prognosis stage.
Finally, effectmodiﬁcationwas tested by an analysis of 2-way interaction
terms between CKD and several variables (blood pressure, gender, age,
history of CVD or heart failure, total cholesterol, and LDL cholesterol).
Interactions between CKD prognosis stage and the variables were also
tested.
The statistical analysis was performed using the Statistical Package
for the Social Sciences (SPSS for Windows, version 19.0; IBM Corp,
Armonk, New York, USA) and STATA 11.0 (STATA 11.0 for Windows,
Stata, College Station, TX, USA).
The study was approved by the Institutional Review Board
of the Ramón y Cajal Hospital (Madrid), and conducted in
accordance with the principles of the Declaration of Helsinki. All
Table 2
Distribution of eGFR stages stratiﬁed by albuminuria stage.
Albuminuria stage
A1 A2 A3
Optimum and high–normal High Very high and nephrotic




>105 45 (1.32) 6 (0.18) 1 (0.03) 52 (1.52)
90–104




75–89 855 (25.10) 66 (1.94) 5 (0.15)
926 
(27.17)
60–74 945 (27.74) 84 (2.47) 3 (0.09)
1,032 
(30.29)
G3a 45–59 623 (18.29) 67 (1.97) 8 (0.23)
698 
(20.48)
G3b 30–44 152 (4.46) 57 (1.67) 7 (0.21) 216 (6.34)
G4 15 22 (0.65) 24 (0.70) 2 (0.06) 48 (1.41)
G5 <15 0 (0.00) 3 (0.09) 0 (0.00) 3 (0.09)
All 3,037 (89.14) 342 (10.04) 28 (0.82) 3,407 (100) 
eGFR: estimated glomerular ﬁltration rate. Values in cells show absolute frequency (relative frequency).
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the study.
5. Results
Table 1 shows the baseline sociodemographic and clinical
characteristics of the MADIABETES CKD Cohort. Mean age was
69 years (SD = 10.8), and the average of duration of DM was
9.1 years (SD = 7.7). The vast majority of patients (90.9%) had a
lowrisk (≤10%)ofdeveloping coronaryeventswithin10 years.However,
28.3% had prior cardiovascular disease (12.7%myocardial infarction, 8.3%
stroke, and 7.3% peripheral artery disease).
The baseline prevalence of CKD was 28.32% (95% CI, 26.84–29.86)
and that of albuminuria was 10.9% (95% CI, 9.9–11.9), with a
predominance of microalbuminuria (10.1%; 95% CI, 9.1–11.1).
Among CKD patients, men had a higher cardiovascular risk than
women; 25.5% had history of myocardial infarction compared with
12.7% in women (p b 0.01). In addition, 18.7% of men had had ≥2Table 3







Yes CI 22.90 20.36–25.66 12.85 10.88–15.11
DI 51.47 44.91–58.72 28.88 24.02–34.43
No CI 8.31 7.28–9.47 3.93 3.23–4.78
DI 17.23 14.94–19.77 8.15 6.60–9.95
CKD Prognosis stage
Low CI 7.95 6.90–9.14 3.75 3.04–4.62
DI 16.44 14.11–19.04 7.76 6.19–9.60
Moderate CI 17.08 14.65–19.81 8.97 7.19–11.13
DI 37.15 31.23–43.87 19.51 15.29–24.53
High CI 26.96 21.64–33.04 14.35 10.40–19.46
DI 61.90 47.46–79.35 32.95 22.68–46.27
Very high CI 36.59 28.60–45.38 24.39 17.65–32.68
DI 89.61 65.37–119.91 59.74 40.31–85.29
CI: Cumulative incidence (%).
DI: Density incidence (per 1000 person-years).cardiovascular events (myocardial infarction, stroke or peripheral
artery disease) compared with 9.3% of women (p b 0.01).
There were signiﬁcant differences for most of the study variables
between patients with and without CKD (Table 1). The only variables
for which differences were not statistically signiﬁcant were use of
statins, REGICOR score, BMI, HbA1c, HDL-C, and TG.
When eGFR and stage of albuminuria were taken into account
(Table 2), 23.89% of patients (95% CI, 22.46–25.32) had a moderate
risk of developing adverse outcomes, 6.75% (95% CI, 5.91–7.59) had a
high risk, and 3.61% (95% CI, 2.98–4.24) had a very high risk.
The variables most strongly associated with the presence of CKD at
baseline were age N 74 years (OR, 19.88; 95% CI, 12.89–30.68), age
60–74 years (OR, 6.22; 95% CI, 4.06–9.53), and albuminuria (OR, 2.27;
95% CI, 1.72–3.00). Other positively associated variables were female
gender (OR, 1.82; 95% CI, 1.49–2.21), hypertension (OR, 1.97; 95% CI,
1.54–2.52), history of myocardial infarction (OR, 1.37; 95% CI, 1.05–
1.78), retinopathy (OR, 1.38; 95% CI, 1.02–1.87), TG ≥150 mg/dl (OR,
1.47; 95% CI, 1.20–1.80), and use of insulin (OR, 1.77; 95% CI 1.40–
2.25) and antiplatelet medication (OR, 1.26; 95% CI, 1.04–1.52).
Finally, DBP b80 mmHg (OR, 0.77; 95% CI, 0.63–0.93), HbA1c b7% (OR,
0.73; 95 CI, 0.60–0.88), and HDL-C ≥45 mg/dl (OR, 0.73; 95% CI, 0.60–
0.89) were inversely associated with CKD.
5.1. Mortality
During the 5-year follow-up, themortality rate was 26.38 cases per
1000 patient-years (95% CI, 23.92–29.01), with higher rates in men
(28.43 per 1000 patient-years; 95% CI, 24.87–32.36) than in women
(24.31 per 1000 patient-years; 95% CI, 21.02–27.98). As for the cause
of mortality, 51.9% of deaths were of cardiovascular origin: 13.69 per
1000 patient-years (95% CI, 11.94–15.62), with no statistically
signiﬁcant predominance of males (15.02 per 1000 patient-years;
95% CI, 12.47–17.95) or females (12.34 per 1000 patient-years; 95% CI,
10.03–15.03).
Of the 965 patients with CKD, 221 died (22.90%; 95% CI, 20.36–
25.66) compared with 203 of 2442 patients without CKD (8.31%; 95%
CI, 7.28–9.47) (p b 0.01) (Table 3). The incidence density was 51.47
cases per 1000 patient-years (95% CI, 44.91–58.72) in CKD patients
compared with 17.23 cases per 1000 patient-years (95% CI, 14.94–
Table 4
Hazard ratios for all-cause mortality for CKD at baseline and albuminuria (Model 1) and CKD risk (Model 2).
A. For the overall sample (n = 3407).
Variables aHRa (95% CI) p value
Model 1 CKD at baseline, Yes With LDL C =114 mg/dl (p50) 1.72 (1.39–2.13) b0.01
With LDL C =135 mg/dl (p75) 2.11 (1.61–2.76) b0.01
With LDL C =153 mg/dl (p90) 3.59 (2.03–6.36) b0.01
Albuminuria, Yes (ref. no) 1.23 (0.94–1.61) 0.13
Model 2 Moderate-risk, Yes (ref. Low-risk) With Age b75 y 2.32 (1.58–3.39) b0.01
With Age ≥75 y 1.27 (0.95–1.69) 0.11
High-risk, Yes (ref. Low-risk) With Age b75 y 2.78 (1.46–5.3) b0.01
With Age ≥75 y 1.78 (1.26–2.52) b0.01
Very-high-risk, Yes (ref. Low-risk) With Age b75 y 4.44 (2.31–8.53) b0.01
With Age ≥75 y 1.80 (1.19–2.72) b0.01
B. Stratiﬁed by gender (men, n = 1713; women, n = 1694).
Model 1 Men
CKD at baseline, Yes (ref. no) 1.44 (1.07–1.93) 0.02
Albuminuria, Yes (ref. no) 1.28 (0.91–1.81) 0.16
Women
CKD at baseline, Yes (ref. no) 1.95 (1.43–2.67) b0.01
Albuminuria, Yes (ref. no) 1.14 (0.73–1.80) 0.56
Model 2 Men
Moderate-risk, Yes (ref. Low-risk) Without Insulin 1.25 (0.86–1.83) 0.24
With Insulin 1.41 (0.77–2.59) 0.27
High-risk, Yes (ref. Low-risk) Without Insulin 1.53 (0.82–2.85) 0.18
With Insulin 2.50 (1.02–4.10) 0.04
Very-high-risk, Yes (ref. Low-risk) Without Insulin 5.09 (2.81–9.22) b0.01
With Insulin 0.94 (0.46–1.92) 0.86
Women
Moderate-risk, Yes (ref. Low-risk) 1.82 (1.28–2.58) b0.01
High-risk, Yes (ref. Low-risk) 2.30 (1.49–3.54) b0.01
Very-high-risk, Yes (ref. Low-risk) 2.73 (1.56–4.77) b0.01
C. Stratiﬁed by history of Cardiovascular disease (Primary Prevention, n = 2646; Secondary Prevention, n = 761).
Primary Prevention
Model 1 CKD at baseline, Yes (ref. no) With cholest. = 172 mg/dl (p25) 1.59 (1.18–2.16) b0.01
With cholest. = 194 mg/dl (p50) 1.99 (1.51–2.63) b0.01
With cholest. = 217 mg/dl (p75) 2.50 (1.78–3.53) b0.01
Albuminuria, Yes (ref. no) 1.51 (1.03–2.21) 0.04
Secondary Prevention
CKD at baseline, Yes (ref. no) 1.62 (1.16–2.27) b0.01
Albuminuria, Yes (ref. no) 1.16 (0.79–1.70) 0.46
Model 2 Primary Prevention
Moderate-risk, Yes (ref. Low-risk) With cholest. = 172 mg/dl (p25) 1.41 (1.01–1.97) 0.04
With cholest. = 217 mg/dl (p75) 1.68 (1.13–2.51) 0.01
High-risk, Yes (ref. Low-risk) With cholest. = 172 mg/dl (p25) 2.29 (1.45–3.62) b0.01
With cholest. = 217 mg/dl (p75) 3.23 (2.06–5.07) b0.01
Very-high-risk, Yes (ref. Low-risk) With cholest. = 172 mg/dl (p25) 2.22 (1.19–4.13) 0.01
With cholest. = 217 mg/dl (p75) 5.73 (3.02–10.9) b0.01
Secondary Prevention
Moderate-risk, Yes (ref. Low-risk) Without Statins 1.42 (0.69–2.91) 0.34
With Statins 1.69 (1.11–2.60) 0.02
High-risk, Yes (ref. Low-risk) Without Statins 2.36 (1.06–5.24) 0.04
With Statins 0.94 (0.49–1.80) 0.85
Very-high-risk, Yes (ref. Low-risk) Without Statins 0.98 (0.34–2.78) 0.97
With Statins 2.62 (1.52–4.49) b0.01
CKD: Chronic Kidney Disease; aHR: adjusted hazard ratio; CI: Conﬁdence Interval; Cardiovascular disease (Myocardial Infarction, Stroke, Peripheral Arterial Disease, Heart failure);
p25: 25th percentile; p50: 50th percentile; p75: 75th percentile; y: years.
a Adjusting for BodyMass Index, Systolic Blood Pressure, Neuropathy, Cholesterol, LDL Cholesterol, Triglycerides, Insulin, Statins, Platelet Antiaggregant drugs, Inhibitors of renin–
angiotensin system.
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signiﬁcant. The remaining mortality rates according to prognosis
stage are shown in Table 3. There were no statistically signiﬁcant
differences between a high and a very high risk of developing adverse
outcomes with respect to all-cause and cardiovascular mortality,
respectively. However, statistically signiﬁcant differences were
observed between the other categories.
The 5-year actuarial survival rate and cardiovascular mortality-free
survival rate for non-CKD patients were signiﬁcantly higher than for
CKDpatients (Supplementary 1, A andC). Stratifying byprognosis stage,
low-risk patients had the highest all-cause mortality-free survival rate(Supplementary 1, B) and cardiovascular mortality-free survival rate
(Supplementary 1, D).
5.2. Factors associated with all-cause mortality
The unadjusted HR for all-cause mortality in patients with CKD at
baseline was 3.02 (95% CI, 2.50–3.66), and the aHR was 1.72 in those
with LDL cholesterol levels of 114 mg/dl (50th percentile of the
distribution of LDL cholesterol values) and 3.59 in those with LDL
cholesterol levels of 153 mg/dl (90th percentile), owing to the effect of
modiﬁcation by LDL cholesterol values (p b 0.01) (Table 4A, model 1).
Table 5
Hazard ratios for cardiovascular mortality for CKD at baseline and albuminuria (Model 1) and CKD risk (Model 2).
A. For the overall sample (n = 3407)
Variables aHRa (95% CI) p value
Model 1 CKD at baseline yes (ref. no) 1.82 (1.36–2.44) b0.01
Albuminuria yes (ref. no) 1.15 (0.80–1.66) 0.45
Model 2 Moderate-risk yes (ref. Low-risk) With Cholesterol = 168 mg/dl (p25) 1.52 (1.08–2.15) b0.01
With Cholesterol = 214 mg/dl (p75) 1.55 (1.05–2.60) 0.03
High-risk yes (ref. Low-risk) With Cholesterol = 168 mg/dl (p25) 1.58 (0.97–2.57) 0.06
With Cholesterol = 214 mg/dl (p75) 2.78 (1.68–4.60) b0.01
Very-high-risk yes (ref. Low-risk) With Cholesterol = 168 mg/dl (p25) 2.03 (1.19–3.46) 0.01
With Cholesterol = 214 mg/dl (p75) 3.89 (2.28–6.67) b0.01
B. Stratiﬁed by gender (men, n = 1713; women, n = 1694).
Model 1 Men
CKD at baseline yes (ref. no) 1.90 (1.27–2.84) b0.01
Albuminuria yes (ref. no) 0.99 (0.62–1.59) 0.98
Women
CKD at baseline yes (ref. no)) With SBP b150 mmHg 1.59 (0.99–2.54) 0.06
With SBP ≥150 mmHg 5.98 (1.71–20.97) b0.01
Albuminuria yes (ref. no) 1.34 (0.75–2.39) 0.33
Men
Model 2 Moderate-risk yes (ref. Low-risk) Without Insulin 1.51 (0.89–2.56) 0.13
With Insulin 1.48 (0.69–3.19) 0.31
High-risk yes (ref. Low-risk) Without Insulin 1.84 (0.80–4.19) 0.15
With Insulin 1.76 (0.73–4.26) 0.21
Very-high-risk yes (ref. Low-risk) Without Insulin 5.54 (2.52–12.18) b0.01
With Insulin 1.06 (0.45–2.51) 0.90
Women
Moderate-risk yes (ref. Low-risk) With LDL C = 97 mg/dl (p25) 1.81 (1.04–3.16) 0.04
With LDL C = 138 mg/dl (p75) 1.41 (0.73–2.74) 0.31
High-risk yes (ref. Low-risk) With LDL C = 97 mg/dl (p25) 1.42 (0.65–3.09) 0.38
With LDL C = 138 mg/dl (p75) 2.96 (1.49–5.87) b0.01
Very-high-risk yes (ref. Low-risk) With LDL C = 97 mg/dl (p25) 2.59 (1.08–6.18) 0.03
With LDL C = 138 mg/dl (p75) 5.15 (2.41–10.98) b0.01
C. Stratiﬁed by History of Cardiovascular disease (Primary Prevention, n = 2646; Secondary Prevention, n = 761).
Model 1 Primary Prevention
CKD at baseline yes (ref. no) 1.82 (1.20–2.75) b0.01
Albuminuria yes (ref. no) 1.92 (1.11–3.30) 0.02
Secondary Prevention
CKD at baseline yes (ref. no) 2.03 (1.34–3.08) b0.01
Albuminuria yes (ref. no) 0.85 (0.52–1.39) 0.52
Model 2 Primary Prevention
Moderate-risk yes (ref. Low-risk) 1.46 (0.91–2.35) 0.12
High-risk yes (ref. Low-risk) 2.57 (1.43–4.65) b0.01
Very-high-risk yes (ref. Low-risk) 4.48 (2.18–9.24) b0.01
Secondary Prevention
Moderate-risk yes (ref. Low-risk) 1.78 (1.13–2.81) 0.01
High-risk yes (ref. Low-risk) 1.44 (0.78–2.67) 0.25
Very-high-risk yes (ref. Low-risk) 2.21 (1.22–4.02) b0.01
CKD: Chronic Kidney Disease; aHR: adjusted hazard ratio; CI: Conﬁdence Interval; Cardiovascular disease (Myocardial Infarction, Stroke, Peripheral Arterial Disease, Heart failure);
p25: 25th percentile; p50: 50th percentile; p75: 75th percentile; y: years.
a Adjusting for BodyMass Index, Systolic Blood Pressure, Neuropathy, Cholesterol, LDL Cholesterol, Triglycerides, Insulin, Statins, Platelet Antiaggregant drugs, Inhibitors of renin–
angiotensin system.
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highest aHR was 4.44 for patients aged b75 years, the very-high-risk
group and 1.80 in patients aged ≥75 years (Table 4A, model 2).
Men with CKD at baseline showed an aHR of 1.44, whereas
women showed an aHR of 1.95 (Table 4B, model 1). However, the
men from the very-high-risk group had a higher risk (aHR, 5.09) than
women (aHR, 2.73), although the differences were not statistically
signiﬁcant because the conﬁdence intervals were over-lapping
(Table 4B, model 2).
In primary prevention, the highest risk of CKD at baseline for
all-cause mortality was found in patients with cholesterol levels of
217 mg/dl (75th percentile). In secondary prevention, the risk of CKD
at baselinewas similar to that of patients without a history of CVD and
with total cholesterol levels of 172 mg/dl (25th percentile) (Table 4C,
model 1).5.3. Factors associated with cardiovascular mortality
Patients with CKD at baseline had an increased risk of cardiovas-
cular mortality (aHR 1.82; 95% CI, 1.36–2.44) (Table 5A, model 1). We
detected an interaction between CKD at baseline and SBP in women
(p = 0.049); data on CKD at baseline revealed a lower risk of
cardiovascular mortality in womenwith SBP b150 mmHg (aHR, 1.59)
than in men (aHR 1.90) regardless of the blood pressure reading (aHR
1.90; 95% CI, 1.27–2.84). However, the CKD at baseline in womenwith
SBP ≥150 mmHg showed a higher risk of cardiovascular mortality
than in men (aHR 5.98) (Table 5B, model 1).
Moreover, CKD at baseline implied a lower risk in patients without
a history of CVD (aHR 1.82) than in patients with prior CVD (aHR
2.03), although the differences were small, and the conﬁdence
intervals were over-lapping (Table 5C, model 1).
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cular mortality (model 2) revealed that an interaction with the total
cholesterol value was detected (p b 0.01). The lower risk of
cardiovascular mortality was seen in the moderate-risk group with
cholesterol levels of 168 mg/dl (25th percentile) and the highest risk
was seen for those included in the very-high-risk group with
cholesterol levels of 214 mg/dl (75th percentile). The differences
between both groups were statistically signiﬁcant because the
conﬁdence intervals did not overlap (Table 5A, model 2).
In men, we detected an interaction between CKD prognosis risk
group and insulin use (p = 0.03), whereas in women an interaction
was observed between prognosis risk group and LDL cholesterol level
(p = 0.02). In men, the highest risk was seen in the very-high-risk
group without use of insulin; in women the highest risk was seen in
the very-high-risk group with LDL cholesterol levels of 138 mg/dl
(75th percentile) (Table 5B, model 2).
The risk of cardiovascular mortality in the very-high-risk group
was higher in patients without history of CVD (aHR, 4.48) than in
those with prior CVD (aHR, 2.21), although the differences were not
statistically signiﬁcant (Table 5C, model 2).
6. Discussion
6.1. Prevalence of CKD
Since the publication of the K/DOQI clinical practice guidelines for
the classiﬁcation of CKD in 2002 (National Kidney Foundation, 2002),
several studies based on this classiﬁcation system have shown high
prevalence estimates for CKD in the general population and in
patients with T2DM. The results of our study show that approximately
a quarter of patients with T2DM have an eGFR below 60 mL/min/
1.73 m2. This result is concordant with those of previous studies in
T2DM performed in Spain (Coll-de-Tuero et al., 2012; Mur Martí,
Villaró Gabarrós, Porta Martínez, & Jaén Manzanera, 2013) and
southern Europe (Targher et al., 2012). However, studies in Italian
hospitals revealed lower ﬁgures, around 19% (Penno et al., 2012).
Patients with DM participating in NHANES III, NHANES 1999–2004,
and NHANES 2005–2008 had a b20% prevalence of stage 3–5 CKD
(CKD-EPI equation) (14.9%, 16.7%, and 17.7%, respectively). The
discrepancy in the prevalence data might be due to the difference in
mean age between the studies (58 vs. 69 years). In addition, in their
study of 2798 DM patients aged 20 years or older from NHANES
2001–2008, Mottl et al. (2013) reported the prevalence of normoal-
buminuric CKD to be 9.7% and that of albuminuria to be 7.6% (CKD-EPI
equation).
Previous data from the ﬁrst epidemiological investigation of the
prevalence of CKD (stages 3–5) in Spanish patients aged ≥20 years
revealed an overall prevalence of 6.8% and a prevalence of 21.42% for
patients aged N64 years. In addition, the prevalence ratiowas 2.0 (95%
CI, 1.4–2.8) among participants with DM (Otero, de Francisco, Gayoso,
García, & EPIRCE Study Group, 2010).
6.2. Prevalence of albuminuria
The proportion of T2DM patients with albuminuria is lower in our
study than that reported in previous studies in Spain (Coll-de-Tuero et
al., 2012). Other DM cohort studies also showed a wide variation in
the prevalence of albuminuria, ranging from 6% to 89% (Fox et al.,
2012). For example, Rodriguez-Poncelas et al. (2014) recently
reported a prevalence of albuminuria of 13.5% in a Spanish cross-
sectional study of 1141 participants with T2DM (aged N40 years).
6.3. Prevalence of risk of adverse outcomes
A high or very high risk of adverse outcomes was recorded in
10.36% of participants, that is, higher than the 5.5% reported in theNHANES III study (Levey et al., 2011). This difference might be
because the NHANES study was a nationally representative sample of
15,625 adults aged ≥20 years with and without DM (Coresh, Astor,
Greene, Eknoyan, & Levey, 2003). Results from 45 cohorts (1,555,332
people) included in a meta-analysis (Levey et al., 2011) indicate that
the risk of lower eGFR and higher levels of albuminuria is well
established for various outcomes: all-cause mortality, cardiovascular
mortality, end-stage renal disease, acute kidney injury, and progres-
sive CKD. The adjusted relative risk is usually higher for kidney
outcomes than for mortality outcomes. Since 2006, the unadjusted
relative risk formortality in participants with reduced kidney function
compared with those without has ranged from 0.94 to 5.0 (Tonelli et
al., 2006).
6.4. CKD-associated factors
The classic factors associated with the presence of CKD are older
age, gender, smoking, black race, low income or education, cardio-
vascular disease, hypertension, DM, duration of DM, and obesity
(Afghahi et al., 2011; Levey et al., 2003); the factors associated with
progression of CKD are poor glycemic control (Bash, Selvin, Steffes,
Coresh, & Astor, 2008), higher blood pressure, lower HDL cholesterol
levels (Zoppini et al., 2009), and higher proteinuria levels (Levey et al.,
2003). Male gender has been associated with CKD in the general
population (Cueto-Manzano et al., 2014) and in patients with DM
(Gall, Hougaard, Borch-Johnsen, & Parving, 1997). However, in our
study, as in other reports, we found an associationwith female gender
(Afghahi et al., 2011; De Pablos-Velasco et al., 2010), possibly owing
to the higher mortality rate in men (survival bias) as a consequence of
their higher cardiovascular risk.
Our ﬁndings revealed other associated factors such as
TG ≥150 mg/dl and use of antiplatelet medication and insulin, as we
found in a previous study of predictors of retinopathy after a 4-year
follow-up (Salinero-Fort et al., 2013). Insulin may be associated with
CKD because it is strongly recommended as ﬁrst-line treatment if
eGFR is b30 mL/min/1.73 m2 andHbA1c is 6.5%–8.5% (Gómez-Huelgas,
Martínez-Castelao, Artola, Górriz, & Menéndez, 2014).
The factors most closely associated with CKD at baseline in the
adjusted multivariable analysis were age 60–74 years and age N74 years
(OR, 5.89 and 13.10, respectively) and albuminuria (OR, 2.61). Other
studies in our setting revealed an association with heart failure, atrial
ﬁbrillation, peripheral arteriopathy, stroke (Salvador González et al.,
2015), and hyperuricemia (De Pablos-Velasco et al., 2010).
Finally, our study showed an association between CKD and
retinopathy, as reported elsewhere (Colhoun et al., 2001). This ﬁnding
is congruent with previous ﬁndings showing that both entities are
microvascular complications in DM patients (Girach & Vignati, 2006).
Therefore, it has been demonstrated that retinal arterioles and
venules are narrowed in renal failure and that the narrowing worsens
as kidney function declines (Ooi et al., 2011). However, to the best of
our knowledge, this is the ﬁrst study to examine the relationship
between CKD and retinopathy among T2DM patients in Spain.
6.5. Mortality
6.5.1. All-cause mortality
Our report shows that the unadjusted HR for all-cause mortality in
patients with eGFR b60 mL/min/1.73 m2was 3.02 (95% CI, 2.50–3.66)
after 5 years of follow-up. This ﬁnding is consistent with those of
other studies in patients with DM (Patel, Young, Ojo, & Hayward,
2005). After adjusting for gender, age, prior cardiovascular disease,
albuminuria, SBP, BMI, total cholesterol, LDL cholesterol, HDL
cholesterol, triglycerides, neuropathy, insulin, statins, antiplatelet
drugs, and inhibitors of the renin–angiotensin system inhibitors, the
HRwas 1.72 (95% CI, 1.39–2.13) in patientswith LDL cholesterol levels
of 114 mg/dl (50th percentile), which is higher than in other studies
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where the adjusted HR was around 1.20 (Weiner et al., 2004). A
possible explanation for this difference is that our study did not
exclude patients with prior cardiovascular disease.
CKD at baseline tended to indicate a lower risk for all-cause
mortality in men (aHR, 1.44; 95% CI, 1.07–1.93) than in women (aHR
1.95; 95% CI, 1.43–2.67), in contrast with other reported studies (Fried
et al., 2005). When at baseline, albuminuria and eGFR were analyzed,
men who did not use insulin and were in the very-high-risk group (eGFR
b60 mL/min/1.73 m2 andmacroalbuminuria, or eGFR b45 mL/min/1.73 m2
and albuminuria 30–299 mg/g, or eGFR b30 mL/min/m2 and
albuminuria b30 mg/g) had an almost 2-fold higher risk of all-cause
mortality than women in the same group (aHR 5.09; 95% CI, 2.81–9.22,
vs. aHR, 2.73; 95% CI, 1.56–4.77). However, these results should be
interpreted with caution because the small sample size limited the
ability to detect differences between both groups.
High total cholesterol levels inﬂuenced the risk for all-cause
mortality in CKD patients with no history of CVD, to the extent that
risk was equal to or greater than that recorded in patients with a prior
history of CVD. These data contrast with those reported by Kovesdy,
Anderson, and Kalantar-Zadeh (2007), who showed that lower lipid
levels were associated with higher mortality in patients who have
moderate and advanced CKD and are not yet on dialysis.
Consistent with our ﬁndings, several studies observed a synergistic
interaction between albuminuria and eGFR that affected all-cause
mortality. For example, in the Kidney Early Evaluation program (KEEP)
(Amin et al., 2013), participants with eGFR b30 mL/min/1.73 m2 and
macroalbuminuria were 5 times more likely to die than participants
with eGFR ≥105 mL/min/m2 and normoalbuminuria (HR, 4.84; 95% CI
3.33–7.04). In participants with eGFR b30 mL/min/1.73 m2, no differ-
ences were observed between microalbuminuria and macroalbumi-
nuria in all-causemortality, but it seems that differenceswere observed
in patients with eGFR N =30 and b60 mL/min/1.73 m2. A recent
10-year cohort study carried out in Taipei (Taiwan) with 646 DM2
patients showed similar results (Yu et al., 2013) for all-cause mortality
with bothproteinuria and eGFR b 60 mL/min/1.73 m2 (HR, 4.01; 95%CI
2.42–6.67).
However, of the 31 studies included in the meta-analysis by
Toyama et al. (2013)), who investigated the impact of albuminuria
and/or low eGFR on the risk of mortality, only 2 reported about the
combined inﬂuence of low eGFR (b60 mL/min/1.73 m2) and albu-
minuria in terms of the risk for the outcomes. Patients with both
albuminuria and eGFR b60 mL/min/1.73 m2 had a 4.20-fold (95% CI
3.11–5.68) higher risk of cardiovascular mortality than those with
neither of these risk factors. In this respect, de Boer et al. (2009)
analyzed a cohort of the Cardiovascular Health Study that included
691 participants with DM. The participants with a normal urine
albumin-to-creatinine-ratio (ACR) and low eGFR had an aHR for
mortality of 1.69, and those with elevated urine ACR and normal eGFR
had an aHR of 1.67. In addition, the aHR was 2.54 if the patients had
both low eGFR and elevated urine ACR.
With regard to studies conducted in the southern Europe, 2 were
included in the meta-analysis of Toyama et al. (2013). Firstly, the
Casale Monferrato study (Bruno et al., 2007) analyzed 1538
participants with DM2 of whom 670 died over an 11-year follow-up
period. In patients with eGFR b60 ml/min/1.73 m2 and microalbumi-
nuria the aHR (adjusted for age and sex) for all-cause mortality was
1.40 (95% CI, 1.05–1.87); in patients with eGFR b60 mL/min/1.73 m2
andmacroalbuminuria it was of 1.79 (95% CI, 1.28–2.50). The aHRs for
cardiovascular mortality were 1.41 (95% CI, 0.91–2.21) and 1.81 (95%
CI, 1.17–2.82), respectively, in the same groups. Secondly, the study of
Casiglia et al. (2000) which was carried out in the Pordenone Diabetic
Care Centre (Italy) followed 683 participants with DM2 for 6 years. A
total of 132 died (19.3%), 10% of cardiovascular causes. Although the
combined effect of impaired renal function and albuminuria was not
analyzed, data showed for cardiovascular mortality an HR of 2.97 formacroalbuminuria (95% CI, 1.56–5.12) and of 2.01 for microalbumi-
nuria (95% CI, 1.15–3.68). The values we recorded were higher when
total cholesterol was high (aHR, 3.89; 95% CI, 2.28–6.67), but similar
when total cholesterol was under 170 mg/dl.
6.5.2. Cardiovascular mortality
With regard to the risk of cardiovascular mortality in patients with
CKD, our results (aHR, 1.82; 95% CI, 1.36–2.44) are similar to those of
the ADVANCE study for eGFR b60 mL/min/1.73 m2 and normoalbu-
minuria (HR, 1.85; 95% CI, 1.17–2.92) (Ninomiya et al., 2009).
Furthermore, the ADVANCE study showed a multivariable aHR for
cardiovascular mortality of 3.26 (95% CI, 2.46–4.32) for T2DM patients
with a urinary albumin creatinine ratio ≥30 and eGFR 30–59 mL/min/
1.73 m2. Our aHR for patients at very high risk of adverse outcomes
and total cholesterol levels of 214 mg/dl (75th percentile) was higher,
with no clear explanation, except that patients at very high risk also
included those who had an eGFR b15 mL/min/1.73 m2.
These ﬁndings support current recommendations to regularly
assess both albuminuria and GFR in the clinical care of patients
with diabetes, especially in primary health care (Martínez-Castelao
et al., 2014).
The strengths of our study include the use of a population-based
cohort, prospective ascertainment of end points, and assessment of
information on potentially confounding variables, which reduces
potential selection and confusion bias. We believe our results are
applicable to other patients with T2DM. Our dataset included patients
from many primary health care centers in Madrid. The range of
patients was broad, namely, men and women aged from 30 years to
N65 years, and the major exposure categories were well represented.
The severity of T2DM at baseline ranged from low (no complications)
to very severe (micro and macrovascular complications). In addition,
in Spain, it is mandatory to register deaths in registries. Registry
information is then submitted to the National Institute of Statistics
(Instituto Nacional de Estadística). Therefore, data about vital status,
and date and cause of death are available for all patients, with no loss
of data during follow-up.
Our study is also subject to a series of limitations. First, the
laboratory data were measured at different primary health care
centers and using different devices; however, all laboratories used
standardmethods. Second, as noted by other authors (Carter, Stevens,
Irving, & Lamb, 2011), the use of the CKD-EPI equation may have led
us to overestimate the prevalence of CKD in the elderly, which could
be a limitation of our study given the characteristics of the cohort.
Third, serum creatinine was measured using an enzymatic creatinine
assay that was not traceable to isotope dilution mass spectrometry
(ID-MS). This is a limitation given that gas chromatography ID-MS
is considered the method of choice for establishing the true
concentration of creatinine in serum (Myers et al., 2006). Fourth,
the determination of microalbuminuria could be affected by the
concomitant use of ACE inhibitors or Angiotensin receptor blockers
and by the presence of urinary tract infections. Therefore, albuminuria
was only considered in the analysis if it was persistent (at least 2 of 3
consecutive samples). However, false negatives can arise because of
medication. Finally, we used the result of a single creatinine
determination to calculate the CKD-EPI equation and estimate GFR.
7. Conclusions
We found a high prevalence of CKD and a low prevalence of
albuminuria in a Spanish cohort of T2DM patients attended in the
primary care setting. The prevalence of CKD at baseline was
signiﬁcantly higher in women than in men, but CKD-associated
mortality was higher in men than in women. Approximately half of
the deaths were due to cardiovascular causes. Baseline CKD is an
independent risk factor for all-cause and cardiovascular mortality in
the overall cohort, as well in separate subsamples of men and women
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heart disease. Albuminuria is an independent risk factor for all-cause
and cardiovascular mortality only in primary prevention.
Classifying patients by prognosis stage based on eGFR and
albuminuria revealed that low-risk patients had the highest all-cause
mortality-free survival rate and cardiovascular mortality-free
survival rate.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2015.10.007.
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